PIERRE PETERLIN

Dr. PIERRE PETERLIN

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
TCThomas Cluzeau
Thomas Cluzeau
MSMarie Sebert
Marie Sebert
RRRamy Rahmé
Ramy Rahmé
SCStefania Cuzzubbo
Stefania Cuzzubbo
JLJacqueline Lehmann-Che
Jacqueline Lehmann-Che
PFPierre Fenaux
Pierre Fenaux
PURPOSE: TP53-mutated ( TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete remission [CR]) with azacitidine (AZA) alone, short response duration, and a median overall survival (OS) of approximately 6 months. Eprenetapopt (APR-246), a novel first-in-class drug, leads to p53 protein reconformation and reactivates its proapoptotic and cell-cycle arrest functions. PATIENTS AND METHODS: This phase II study assessed the safety and efficacy of eprenetapopt in combination with AZA in untreated high or very high International Prognostic Scoring System-R TP53m MDS and AML patients. RESULTS: Fifty-two TP53m patients (34 MDS, 18 AML [including seven with more than 30% blasts]) were enrolled. In MDS, we observed an overall response rate (ORR) of 62%, including 47% CR, with a median duration of response at 10.4 months. In AML, the ORR was 33% including 17% CR (27% and 0% CR in AML with less than and more than 30% marrow blasts, respectively). Seventy-three percent of responders achieved TP53 next-generation sequencing negativity (ie, variant allele frequency < 5%). The main treatment-related adverse events were febrile neutropenia (36%) and neurologic adverse events (40%), the latter correlating with a lower glomerular filtration rate at treatment onset ( P < .01) and higher age ( P = .05), and resolving with temporary drug interruption without recurrence after adequate eprenetapopt dose reduction. With a median follow-up of 9.7 months, median OS was 12.1 months in MDS, and 13.9 and 3.0 months in AML with less than and more than 30% marrow blasts, respectively. CONCLUSION: In this very high-risk population of TP53m MDS and AML patients, eprenetapopt combined with AZA was safe and showed potentially higher ORR and CR rate, and longer OS than reported with AZA alone.

1 November 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
Eunice S WangEunice S Wang
Eunice S Wang
PMPau Montesinos
Pau Montesinos
JFJames Foran
James Foran
HEHarry Erba
Harry Erba
EREduardo Rodríguez-Arbolí
Eduardo Rodríguez-Arbolí
AVAdriano Venditti
Adriano Venditti
PURPOSE: Ziftomenib—a potent, highly selective, oral menin inhibitor—was well tolerated and demonstrated encouraging clinical activity as monotherapy for relapsed/refractory NPM1 -mutated ( NPM1 -m) and KMT2A -rearranged AML in the KOMET-001 phase I trial. METHODS: In the registration-enabling phase II part of KOMET-001, patients with relapsed/refractory NPM1 -m AML received ziftomenib 600 mg once daily. The primary end point was the rate of complete remission with full hematologic recovery (CR)/CR with partial hematologic recovery (CRh). RESULTS: From January 26, 2023, to May 13, 2024, 92 patients (median age, 69 years [range, 33-84]) were treated. The primary end point was met, with a CR/CRh rate of 22% (95% CI, 14 to 32; P = .0058); 61% were negative for measurable residual disease. Overall response rate was 33% (95% CI, 23 to 43), with a median duration of 4.6 months (95% CI, 2.8 to 7.4). Prespecified subgroup analyses showed comparable CR/CRh regardless of previous therapy, including venetoclax, or type of comutations. Median overall survival was 6.6 months (95% CI, 3.6 to 8.6). Common grade ≥3 treatment-emergent adverse events were febrile neutropenia (26%), anemia (20%), and thrombocytopenia (20%). Differentiation syndrome occurred in 25% of patients (15% grade 3; no grade 4-5) and was manageable with protocol-defined mitigation. Three patients (3%) discontinued treatment because of ziftomenib-related adverse events. CONCLUSION: Ziftomenib demonstrated significant clinical benefit and deep responses in patients with heavily pretreated, relapsed/refractory NPM1 -m AML. Ziftomenib was well tolerated with a safety profile consistent with previous studies, including manageable differentiation syndrome, lack of clinically significant QTc prolongation, and low rates of myelosuppression.

21 April 2017 in Mycoses
Verified
Journal Article
Closed access
PDF file
JBJessie Bourcier
Jessie Bourcier
PHPierre‐Marie Heudes
Pierre‐Marie Heudes
FMFlorent Morio
Florent Morio
TGThomas Gastinne
Thomas Gastinne
PCPatrice Chevallier
Patrice Chevallier
PPPIERRE PETERLIN
PIERRE PETERLIN

10 October 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
UPUwe Platzbecker
Uwe Platzbecker
LALionel Adès
Lionel Adès
PMPau Montesinos
Pau Montesinos
EAEmanuele Ammatuna
Emanuele Ammatuna
PFPierre Fenaux
Pierre Fenaux
SZSven Zukunft
Sven Zukunft
PURPOSE: The phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) regimen (ATRA and ATO [ATRA-ATO]) plus low-dose idarubicin versus standard ATRA plus anthracycline-based chemotherapy (ATRA-CHT) regimen (ie, ATRA and idarubicin regimen) in patients with high-risk acute promyelocytic leukemia (APL; EudraCT 2015-01151-68; ClinicalTrials.gov identifier: NCT02688140 ). METHODS: Adult patients with newly diagnosed high-risk APL in the ATRA-ATO arm received ATO 0.15 mg/kg once daily and ATRA 45 mg/m 2 twice daily until complete remission (CR), with two doses of idarubicin 12 mg/m 2 on days 1 and 3, followed by consolidation therapy (four ATRA-ATO cycles). Patients in the ATRA-CHT arm received induction with ATRA 45 mg/m 2 twice daily and idarubicin 12 mg/m 2 once daily on days 1, 3, 5, and 7, followed by three cycles of chemotherapy-based consolidation and 2 years of maintenance therapy. The primary study end point was event-free survival (EFS) at 2 years. RESULTS: As of July 2022, 133 eligible patients had received either ATRA-ATO (n = 68) or ATRA-CHT (n = 65). The study was discontinued prematurely because of slow accrual during the COVID-19 pandemic. After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm (HR, 0.4 [95% CI, 0.17 to 0.92]; log-rank test P = .02). At a median of 7.8 and 12.1 months from achievement of CR, molecular relapse occurred in one (1.5%) ATRA-ATO patient versus eight (12.3%) ATRA-CHT patients ( P = .014). Overall, 32% and 68% of patients receiving ATRA-ATO and ATRA-CHT, respectively, reported serious treatment-emergent adverse events ( P < .01). CONCLUSION: The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk APL.

8 November 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RBRobin Boutault
Robin Boutault
PPPIERRE PETERLIN
PIERRE PETERLIN
MBMarouane Boubaya
Marouane Boubaya
KSKatja Sockel
Katja Sockel
PCPatrice Chevallier
Patrice Chevallier
BEbene Eveillard
bene Eveillard

25 May 2023 in The Lancet Haematology
Verified
Journal Article
Closed access
PPPIERRE PETERLIN
PIERRE PETERLIN
YBYannick Le Bris
Yannick Le Bris
PTPascal Turlure
Pascal Turlure
PCPatrice Chevallier
Patrice Chevallier
AMAudrey Ménard
Audrey Ménard
PFPierre Fenaux
Pierre Fenaux